Phase II Trial of B-DIM (DIM: 3,3 diindolylmethane) on Intermediate Endpoint Biomarkers in Patients with Prostate Cancer who are Undergoing Prostatectomy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Diindolylmethane (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
Most Recent Events
- 19 Mar 2018 Biomarkers information updated
- 03 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Nov 2011 Planned end date changed from 1 Sep 2010 to 1 Jan 2014 as reported by ClinicalTrials.gov.